Xenon Current Deferred Revenue vs Revenue Per Share Analysis

XENE Stock  USD 41.88  0.17  0.40%   
Xenon Pharmaceuticals financial indicator trend analysis is more than just analyzing Xenon Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Xenon Pharmaceuticals is a good investment. Please check the relationship between Xenon Pharmaceuticals Current Deferred Revenue and its Revenue Per Share accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.

Current Deferred Revenue vs Revenue Per Share

Current Deferred Revenue vs Revenue Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Xenon Pharmaceuticals Current Deferred Revenue account and Revenue Per Share. At this time, the significance of the direction appears to have very week relationship.
The correlation between Xenon Pharmaceuticals' Current Deferred Revenue and Revenue Per Share is 0.22. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Revenue Per Share in the same time period over historical financial statements of Xenon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Xenon Pharmaceuticals' Current Deferred Revenue and Revenue Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Xenon Pharmaceuticals are associated (or correlated) with its Revenue Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Revenue Per Share has no effect on the direction of Current Deferred Revenue i.e., Xenon Pharmaceuticals' Current Deferred Revenue and Revenue Per Share go up and down completely randomly.

Correlation Coefficient

0.22
Relationship DirectionPositive 
Relationship StrengthVery Weak

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.
Most indicators from Xenon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Xenon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.At present, Xenon Pharmaceuticals' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 2.2 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 2.65.

Xenon Pharmaceuticals fundamental ratios Correlations

0.970.430.990.30.97-0.460.960.01-0.59-0.980.980.660.870.840.760.960.520.98-0.270.960.70.030.65-0.450.96
0.970.370.980.31.0-0.360.990.08-0.71-0.980.970.770.920.790.660.980.440.98-0.20.930.760.080.65-0.360.98
0.430.370.440.280.38-0.680.27-0.1-0.05-0.440.370.150.310.40.660.380.070.45-0.40.510.26-0.070.67-0.610.38
0.990.980.440.370.98-0.440.970.1-0.62-0.990.970.70.90.850.740.960.50.98-0.260.950.760.080.63-0.430.96
0.30.30.280.370.260.160.310.84-0.06-0.350.350.110.280.230.270.30.180.260.320.280.580.80.030.20.3
0.971.00.380.980.26-0.40.990.05-0.71-0.980.970.770.920.80.660.980.450.99-0.240.930.740.030.67-0.390.98
-0.46-0.36-0.68-0.440.16-0.4-0.320.450.10.41-0.39-0.15-0.27-0.67-0.48-0.39-0.28-0.50.92-0.550.00.67-0.770.94-0.39
0.960.990.270.970.310.99-0.320.14-0.71-0.960.970.760.890.820.620.980.510.97-0.180.930.780.090.59-0.310.98
0.010.08-0.10.10.840.050.450.14-0.14-0.050.080.130.050.04-0.10.10.15-0.010.470.010.50.8-0.290.50.09
-0.59-0.71-0.05-0.62-0.06-0.710.1-0.71-0.140.62-0.54-0.99-0.58-0.53-0.37-0.74-0.55-0.650.04-0.54-0.66-0.03-0.430.12-0.74
-0.98-0.98-0.44-0.99-0.35-0.980.41-0.96-0.050.62-0.97-0.7-0.93-0.79-0.75-0.95-0.44-0.980.21-0.93-0.74-0.1-0.640.4-0.95
0.980.970.370.970.350.97-0.390.970.08-0.54-0.970.610.910.790.650.950.390.97-0.230.950.70.090.63-0.390.95
0.660.770.150.70.110.77-0.150.760.13-0.99-0.70.610.640.580.470.790.560.72-0.050.610.70.050.47-0.170.79
0.870.920.310.90.280.92-0.270.890.05-0.58-0.930.910.640.610.520.840.130.89-0.150.790.650.10.5-0.260.84
0.840.790.40.850.230.8-0.670.820.04-0.53-0.790.790.580.610.630.830.710.84-0.580.860.62-0.210.63-0.570.83
0.760.660.660.740.270.66-0.480.62-0.1-0.37-0.750.650.470.520.630.680.520.73-0.150.730.610.080.55-0.490.69
0.960.980.380.960.30.98-0.390.980.1-0.74-0.950.950.790.840.830.680.570.98-0.220.940.780.060.68-0.381.0
0.520.440.070.50.180.45-0.280.510.15-0.55-0.440.390.560.130.710.520.570.48-0.20.510.48-0.020.33-0.260.57
0.980.980.450.980.260.99-0.50.97-0.01-0.65-0.980.970.720.890.840.730.980.48-0.320.970.71-0.020.72-0.50.98
-0.27-0.2-0.4-0.260.32-0.240.92-0.180.470.040.21-0.23-0.05-0.15-0.58-0.15-0.22-0.2-0.32-0.370.20.82-0.60.85-0.22
0.960.930.510.950.280.93-0.550.930.01-0.54-0.930.950.610.790.860.730.940.510.97-0.370.66-0.050.74-0.550.94
0.70.760.260.760.580.740.00.780.5-0.66-0.740.70.70.650.620.610.780.480.710.20.660.490.260.050.78
0.030.08-0.070.080.80.030.670.090.8-0.03-0.10.090.050.1-0.210.080.06-0.02-0.020.82-0.050.49-0.360.650.06
0.650.650.670.630.030.67-0.770.59-0.29-0.43-0.640.630.470.50.630.550.680.330.72-0.60.740.26-0.36-0.810.68
-0.45-0.36-0.61-0.430.2-0.390.94-0.310.50.120.4-0.39-0.17-0.26-0.57-0.49-0.38-0.26-0.50.85-0.550.050.65-0.81-0.38
0.960.980.380.960.30.98-0.390.980.09-0.74-0.950.950.790.840.830.691.00.570.98-0.220.940.780.060.68-0.38
Click cells to compare fundamentals

Xenon Pharmaceuticals Account Relationship Matchups

Xenon Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding25.9M34.5M43.6M60.5M66.9M70.2M
Total Assets147.7M189.2M572.0M754.1M964.8M1.0B
Short Long Term Debt Total16.5M3.3M8.3M10.4M10.9M10.0M
Other Current Liab6.3M7.8M9.9M13.7M17.4M18.2M
Total Current Liabilities43.4M14.8M14.3M22.7M27.3M17.3M
Total Stockholder Equity92.0M171.4M550.0M721.5M927.9M974.3M
Property Plant And Equipment Net2.6M6.9M12.5M16.9M18.8M19.8M
Net Debt(8.3M)(41.7M)(167.4M)(46.8M)(137.7M)(130.9M)
Retained Earnings(249.7M)(278.5M)(357.4M)(482.7M)(665.1M)(631.9M)
Accounts Payable2.5M3.0M3.8M8.5M8.6M9.0M
Cash24.8M45.0M175.7M57.2M148.6M156.1M
Non Current Assets Total2.8M7.4M13.0M153.8M319.8M335.8M
Non Currrent Assets Other2.6M7.4M8.1M7.8M7.4M7.8M
Cash And Short Term Investments141.4M177.0M551.8M592.1M638.1M670.0M
Net Receivables813K1.8M2.8M986K874K872.3K
Common Stock Total Equity294.2M397.7M783.2M1.1B1.2B1.3B
Liabilities And Stockholders Equity147.7M189.2M572.0M754.1M964.8M1.0B
Non Current Liabilities Total12.3M3.1M7.7M9.9M9.6M7.2M
Other Current Assets2.7M3.0M4.5M7.2M6.0M6.3M
Other Stockholder Equity40.6M45.4M117.5M142.1M156.8M164.6M
Total Liab55.7M17.8M22.0M32.6M36.9M27.2M
Total Current Assets144.9M181.8M559.0M600.3M645.0M677.2M
Common Stock294.2M397.7M783.2M1.1B1.4B1.5B
Property Plant Equipment1.7M3.6M4.5M6.5M7.5M7.8M
Net Tangible Assets84.2M163.6M542.3M721.5M829.7M871.2M
Other Assets238K523K465K143.7M306.2M321.5M
Short Term Investments116.6M132.0M376.1M534.8M489.4M513.9M
Retained Earnings Total Equity(249.7M)(278.5M)(357.4M)(482.7M)(434.5M)(412.7M)
Capital Surpluse40.6M45.4M117.5M142.1M163.4M171.6M
Net Invested Capital99.8M163.6M542.3M721.5M927.9M974.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.81)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.19)
Return On Equity
(0.27)
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.